Table 2.

Changes in weight and blood pressure relative to placebo following 1-year treatment with drugs approved for long-term weight management

Drug	% Weight change	SBP change, mmHg	DBP change, mmHg
Orlistat*	−3.0 (~)	−1.1	−1.1
Lorcaserin	−3.3	−0.7	−0.6
Liraglutide 3.0 mg	−5.2	−2.8	−0.9
Phentermine/Topiramate	−8.9	−3.1	−1.0
Naltrexone/Bupropion	−4.2	+1.5	+1.2

^*Orlistat-associated weight change: Approximate estimate based on various meta-analyses and systematic reviews that included different RCTs of various durations [69–71]; Orlistat-associated change in blood pressure is based on a recent meta-analysis [72]. For all other drugs, the results are based on pooled data of phase 3 RCTs in patients with obesity without diabetes as drawn from the FDA advisory committee briefing documents [73]. When more than one dose was studied, results shown are the ones for the most effective dose.